Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has released a positive earnings forecast, expecting a net profit growth of no less than 34% year-on-year for 2025, with projected revenue of at least 3 billion HKD (up 16% or more) and adjusted net profit of no less than 3.8 billion HKD (up 40% or more) [6] - The company is focusing on a dual-driven strategy of "internal growth + external expansion," which is expected to reshape the value of the beauty industry [6] - The company has successfully integrated acquired brands, enhancing its operational capabilities and expanding its business footprint [7] - The company aims to establish a "super brand, super chain, and super digitalization" strategy to create new value spaces in the beauty industry [8] Financial Summary and Valuation Metrics - For 2025, the company is projected to achieve a revenue of 3,007 million HKD, representing a year-on-year growth of 16.9% [10] - The net profit for 2025 is expected to be 342 million HKD, reflecting a year-on-year increase of 49.6% [10] - The projected EPS for 2025 is 1.4 HKD, with a corresponding P/E ratio of 18.0 times [10]
美丽田园医疗健康（02373）：港股公司信息更新报告：2025年业绩高增，内生+外延重塑美业价值新空间